Conley Chee - 06 Oct 2022 Form 4/A - Amendment Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Commercial Officer
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Issuer symbol
SYRS
Transactions as of
06 Oct 2022
Net transactions value
$0
Form type
4/A - Amendment
Filing time
11 Oct 2022, 16:55:45 UTC
Date Of Original Report
11 Oct 2022
Previous filing
17 Feb 2022
Next filing
11 Oct 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Stock Option (right to buy) Award $0 +44,500 $0.000000 44,500 06 Oct 2022 Common Stock 44,500 $6.73 Direct F1
transaction SYRS Restricted Stock Units Award $0 +34,000 $0.000000 34,000 06 Oct 2022 Common Stock 34,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option becomes exercisable as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.
F2 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
F3 These RSUs will vest as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.

Remarks:

This amendment to the Statement of Changes in Beneficial Ownership of Securities is being filed to correct a typographical error in the "Date of Earliest Transaction" reported on behalf of the reporting person on October 11, 2022. Exhibit 24: Power of Attorney